ROIV Jan 2026 12.500 call
| Previous close | 2.9100 |
| Open | 2.9100 |
| Bid | 2.4000 |
| Ask | 3.2000 |
| Strike | 12.50 |
| Expiry date | 2026-01-16 |
| Day's range | 2.9100 - 2.9100 |
| Contract range | N/A |
| Volume | |
| Open interest | 323 |
Simply Wall St.Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their...
GlobeNewswireRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
PR NewswireRoivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
